Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Aytu Biopharma (AYTU) has 4 years of Operating Leases data on file, last reported at $2.4 million in Q1 2022.

• Operating Leases for Q1 2022 came in at $2.4 million, down 31.26% year-over-year; the trailing twelve-month figure through Mar 2022 was $2.4 million (down 31.26% YoY), and the FY2021 annual result was $2.6 million, up 261.93% from the prior year.
• Operating Leases declined to $2.4 million in Q1 2022 per AYTU's latest filing, from $2.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $3.5 million in Q1 2021 and troughed at $211056.0 in Q4 2020.
• A 4-year average of $1.6 million and a median of $1.1 million in 2020 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2020 and 2021: Operating Leases sank 43.72% in 2020, then jumped 1186.86% in 2021.
• A 4-year view of Operating Leases shows it stood at $375000.0 in 2019, then slumped by 43.72% to $211056.0 in 2020, then jumped by 1186.86% to $2.7 million in 2021, then slipped by 11.41% to $2.4 million in 2022.
• Business Quant data shows AYTU's Operating Leases at $2.4 million in Q1 2022, $2.7 million in Q4 2021, and $2.8 million in Q3 2021.